User profiles for Melanie Davies
 | Professor Melanie J DaviesDiabetes Research Centre, University of Leicester Verified email at uhl-tr.nhs.uk Cited by 89493 |
Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study …
MJ Davies, DA D'Alessio, J Fradkin, WN Kernan… - Diabetes …, 2018 - Am Diabetes Assoc
The American Diabetes Association and the European Association for the Study of Diabetes
convened a panel to update the prior position statements, published in 2012 and 2015, on …
convened a panel to update the prior position statements, published in 2012 and 2015, on …
2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European …
The American Diabetes Association and the European Association for the Study of Diabetes
have briefly updated their 2018 recommendations on management of hyperglycemia, …
have briefly updated their 2018 recommendations on management of hyperglycemia, …
[HTML][HTML] Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes
Background Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and
glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of …
glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of …
Semaglutide 2· 4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled …
M Davies, L Færch, OK Jeppesen, A Pakseresht… - The Lancet, 2021 - thelancet.com
Background This trial assessed the efficacy and safety of the GLP-1 analogue once a week
subcutaneous semaglutide 2·4 mg versus semaglutide 1·0 mg (the dose approved for …
subcutaneous semaglutide 2·4 mg versus semaglutide 1·0 mg (the dose approved for …
[HTML][HTML] Once-weekly semaglutide in adults with overweight or obesity
…, RL Batterham, S Calanna, M Davies… - … England Journal of …, 2021 - Mass Medical Soc
Background Obesity is a global health challenge with few pharmacologic options. Whether
adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 …
adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 …
Type 2 diabetes
415 million people live with diabetes worldwide, and an estimated 193 million people have
undiagnosed diabetes. Type 2 diabetes accounts for more than 90% of patients with …
undiagnosed diabetes. Type 2 diabetes accounts for more than 90% of patients with …
[HTML][HTML] Sedentary time in adults and the association with diabetes, cardiovascular disease and death: systematic review and meta-analysis
Methods Medline, Embase and the Cochrane Library databases were searched for terms
related to sedentary time and health outcomes. Cross-sectional and prospective studies were …
related to sedentary time and health outcomes. Cross-sectional and prospective studies were …
[HTML][HTML] Semaglutide in patients with heart failure with preserved ejection fraction and obesity
Background Heart failure with preserved ejection fraction is increasing in prevalence and is
associated with a high symptom burden and functional impairment, especially in persons …
associated with a high symptom burden and functional impairment, especially in persons …
[HTML][HTML] Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for …
MJ Davies, DA D'Alessio, J Fradkin, WN Kernan… - Diabetologia, 2018 - Springer
The American Diabetes Association and the European Association for the Study of Diabetes
convened a panel to update the prior position statements, published in 2012 and 2015, on …
convened a panel to update the prior position statements, published in 2012 and 2015, on …
Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial
D Rubino, N Abrahamsson, M Davies, D Hesse… - Jama, 2021 - jamanetwork.com
Importance The effect of continuing vs withdrawing treatment with semaglutide, a glucagon-like
peptide 1 receptor agonist, on weight loss maintenance in people with overweight or …
peptide 1 receptor agonist, on weight loss maintenance in people with overweight or …